Five Oral Immunotherapy Vaccines Treating Women’s Diseases Enter Clinical Studies
V-Endo vaccine candidate for endometriosis treatment entered Phase 1/2 study
A biopharmaceutical company announced that it has developed 5 new immunotherapeutic (orally) delivered vaccines targeting gynecological conditions, including breast cancer and endometriosis.
Unlike injectable cancer vaccines, oral vaccines use cells from the gastrointestinal tract to activate the immune system.
Additionally, this new vaccine formulation is stable at room temperature, which improves its use and delivery.
“We are proud of achieving such a feat – in less than a year we have, in collaboration with a major academic institution, developed, manufactured, and evaluated the safety of 5 new orally-delivered vaccines,” Allen Bain, Ph.D., director of Immunitor, said in a press release.
“In addition, we have made the first in the world vaccine, V-Endo, for endometriosis.”
Endometriosis happens when the lining of the uterus (womb) grows outside of the uterus. It may affect more than 11 percent of American women between 15 and 44.
The V-Endo vaccine candidate is being evaluated in a Phase 1/2 clinical trial is meant to be taken orally, leading to improved immune tolerance and anti-inflammatory effects.
This company, Immunitor Inc., a commercial stage biopharmaceutical company, is also recruiting participants for its Phase 2 trial to evaluate the safety of the tablet-formulated V3-Myoma vaccine candidate for women with uterine fibroids, also known as myoma, which are benign tumors that grow in the uterus.
V3-Myom is based on dehydrated proteins collected from inactivated blood and tumor tissues of patients with uterine myoma.
This vaccine candidate is expected to trigger a specific anti-cancer immune response and anti-inflammatory effect.
Three of the vaccine candidates were developed to treat the most prevalent cancers in women, and are in various stages of Phase 2 studies:
- V3-OVA NCT03556566 for ovarian cancer,
- V3-CERVIX NCT03550755 for cervical cancer,
- V3-MOMMO NCT03572361 for breast cancer.
Dr. Allen Bain commented: “Immunitor strives to help women who often have no treatment options and our preliminary investigations have shown very promising results.”